Kineta Presenting at Multiple Investor Conferences in March 2021 Seattle, WA -- (March 3, 2021) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapie ...

Kineta Announces First Participant Dosed in Phase 1 Clinical Trial of KCP506, A Novel Non-Opioid for the  Treatment of Chronic Pain Seattle, WA -- (December 15, 2020) Kineta Inc, through its subsidia ...

Kineta Presents New Preclinical Data at ESMO Virtual Congress 2020 on its VISTA Antagonist Antibodies Seattle, WA -- (December 9, 2020) Kineta, Inc., a clinical stage biotechnology company focused o ...

Kineta Presents New Preclinical Data at the 2020 SITC Annual Meeting on its VISTA Antagonist Antibodies Preclinical data demonstrates that VISTA is a novel target checkpoint against immunosuppressive ...

Kineta Presents New Preclinical Data on VISTA Antagonist Antibodies at AACR Conference on Tumor Immunology and Immunotherapy Seattle, WA -- (October 20, 2020) Kineta, Inc., a clinical stage biotechno ...

Collaboration to advance a first-in-class α9/α10 nAchR antagonist for the treatment of chronic pain into Phase 1 clinical trials Seattle, WA -- (October 7, 2020) Kineta Chronic Pain, LLC, a subsidi ...

Kineta to Participate in BIO Investor Forum Digital Seattle, WA -- (October 2, 2020) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncolo ...

Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506 First in-human clinical trials will evaluate the safety and pharmacokinetics of a first-in-class α9α10 nicotini ...

Kineta Invited to Present at August 2020 Investor Conferences Seattle, WA -- (July 30, 2020) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies i ...

Kineta Announces Formation of New Immuno-oncology Focused Scientific Advisory Board Seattle, WA -- (April 21, 2020) Kineta, Inc., a clinical stage biotechnology company focused on the development of ...